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Human beta-defensin-1 (HBD-1), a peptide released by the immune system, has been 
investigated for its association with periodontal disease. Several studies have found positive 
findings of its expression related to disease progression, whereas others have reported some 
tendencies. This review highlights studies associated with HBD-1 and periodontal disease in 
both primary and clinical investigations, as well as the underlying mechanism and discusses 
further research possibilities for HBD-1. HBD-1 acts as an innate immune apparatus and 
mediating the adaptive immune system; therefore, its role in the pathogenesis of a periodontal 
disease is indisputable. HBD-1 is mainly expressed in the oral stratified epithelium and sulcular 
epithelium, where the barrier junction properties (e.g., E-cadherin and β-catenin in the adherent 
junction) of the gingival epithelial cells serve as the first line of defense against periodontal 
infection. The HBD-1-reinforced epithelium therefore provides both a mechanical and a 
chemical barrier action. Critical issues that arise in the gingival epithelium can therefore be 
alleviated by modulation of HBD-1 production to enhance its protective function. The 
antimicrobial, anti-inflammatory, and wound healing properties of HBD-1 support its use as a 
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Human beta-defensins (HBDs), which are peptides 
secreted by the immune system, are presently under 
investigation for their association with the balance 
between healthy and disease states.1 They exhibit broad-
spectrum antimicrobial activity against bacteria by 
deactivating the lipopolysaccharide (LPS) activity of 
gram-negative bacteria,2 and they are effective against 
fungi and some viruses.3 Recently, among the 31 known 
sub-families of HBDs, three (HBD-1, HBD-2, and HBD-
3) have been investigated for their association with 
maintaining homeostasis in humans.4–6 HBD-1 has a 
broader antimicrobial action than other HBDs and is 
active against both gram-negative and gram-positive 
bacteria.7 The mechanism of this antibacterial action, as 
determined by scanning electron microscopy studies, 
involves entrapment of the bacteria by nets of HBD-1 as 
observed following incubation of Escherichia coli (E. 
coli) with HBD-1.8 These findings suggest that, in theory, 
HBD-1 should show a consistent presence and influence. 
However, clinical investigations of HBD-1 levels and 
periodontal status have variously reported positive 
results, a positive trend, and even no association.7,9–14  
 
HBD-1 gene polymorphisms are suspected to be 
confounding factors that could explain these inconsistent 
results.11,15 Several studies have therefore focused on 
52G>A (rs1799946), -44C>G (rs1800972), and -20G>A 
(rs11362) polymorphisms.16–21 The results point to a 
possible relationship between DEFB1 (the gene for 
HBD-1) and the development of periodontal disease.16 
However, the effects of these variants of DEFB1 on 
HBD-1 secretion or periodontal tissue modification are 
unknown. 
 
Evidence is presently lacking for an association 
between HBD-1 and periodontal disease, either in vitro, 
in vivo, or in clinical studies. Some niches and pathways 
remain in question, so more precise, detailed, and 
focused studies are needed to explore the influence of 
HBD-1 on periodontal disease. The aim of this review 
article is to discuss the presence of HBD-1 and its 
function in the pathogenesis of periodontal disease based 
on existing in vitro, in vivo, and clinical studies. In 
particular, studies of DEFB1 polymorphism are 
highlighted, and suggestions are made for further 
investigations that could provide better insight and 
understanding for researchers and clinicians. 
 
This review follows the Participant Intervention 
Comparison Outcome (PICO) guidelines.22 The 
participants/population are cells, animals, and/or subjects 
related to periodontal disease with or without 
intervention, which is inflammation-related stimulation. 
Non-periodontal disease, as the negative control, is used 
for comparison. The measured outcome is HBD-1 
production (gene expression, protein levels, and location) 
or DEFB1 detection. The literature search was conducted 
using electronic databases, including PubMed, Scopus, 
and EBSCO. Keywords were “Human Beta Defensin-1,” 
“HBD-1,” “Defensin-1,” “DEFB1,” “Periodontitis,” and 
“Periodontal disease.” In vitro, in vivo, and clinical 
studies written as full texts in English and published 
within the past 10 years were included in the review. 
Duplications and studies limited to abstracts were 
excluded from this analysis. Manual screening for critical 
appraisal was achieved from supporting journals. All 
journal papers included in this review are discussed and 




Three beta-defensins have been identified in humans, 
namely human beta-defensin-1 (HBD-1), HBD-2, and 
HBD-3.23 Both HBD-1 and HBD-3 exhibit antimicrobial 
effect against gram-positive and gram-negative bacteria, 
as well as adenoviruses,24,25 whereas HBD-2 specifically 
targets gram-negative bacteria and Candida albicans.26 
In addition, HBD-2 is tenfold more effective than HBD-1 
against E. coli.26 HBD-1 is a small cysteine-rich protein 
weighing less than seven kDa and containing three 
disulfide bonds.27 It is naturally produced by epithelial 
cells7,14,28 and is constitutively expressed in skin 
keratinocytes and in urinary and respiratory tract 
epithelial cells, as well in gingival epithelial cells.29–32 Its 
expression can also be detected in saliva and gingival 
crevicular fluid.33–35 Given its location, HBD-1 
represents the first line of defense against invading 
periodontal pathogens. 
 
In their association with systemic disease, defensins 
are known to maintain homeostasis by restraining 
bacterial overgrowth and fending off commensals and 
pathogens.36,37 HBD-1 reportedly exerts its antimicrobial 
activity by modulating the human intestinal microbiota.38 
In vivo studies on the human colon have localized HBD-
1 in the mucus,39 while HBD-1 is also expressed in the 
urinary system, including the bladder, distal nephrons of 
the kidney,40 distal ureter,41 and urothelium.42 The 
finding that the mRNA level for HBD-1 was ten times 
higher in the kidney than in the ureter and bladder41 has 
been considered to reflect an abundant expression of 
HBD-1 by the epithelial lining of the nephron and 
secretion of HBD-1 into the urinary tract.40 HBD-1 levels 
are increased in pyelonephritis patients,43 and HBD-1 
shows elevated antibacterial activity against Escherichia 
coli in an in vitro inflammatory disease model of the 
urinary tract.43 In vivo investigation using Beta Defensin-
1  (DEFB-1)  knockout  (DEFB1-/-) mice also revealed an 
increased risk of bacteriuria in the absence of HBD-1 
expression.42   An  in  vivo  study of the protective role of 
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HBD-1 in a mouse model of urinary tract disease showed 
that HBD-1 prevented spontaneous infection based on the 
bacterial inoculation level. HBD-1 prevented infection 
against inoculations of 104 to 106 CFU of E. coli, but not 
against an inoculation of 108 CFU,44 suggesting that 
HBD-1 secretion via mucus and HBD-1 expression in the 
urinary tract resolved the infection and aided the immune 
system in maintaining homeostasis.  
 
ROLE OF HUMAN BETA-DEFENSIN-1 IN THE 
PATHOGENESIS OF PERIODONTAL DISEASE 
 
Several clinical investigations have attempted to 
confirm the function of HBD-1 and to find the link 
between its level and periodontal disease severity. 
Patients with periodontitis showed higher HBD-1 mRNA 
expression than healthy subjects, and HBD-1 showed the 
highest expression among all HBD forms.13 The 
association between HBD-1 and inflammation was also 
determined to be mediated by tumor necrosis factor α 
(TNFα). In young children, mRNA expression of HBD-1 
was correlated with the expression level of TNFα mRNA 
(r = 0.668, p<0.0025).28  
 
However, other clinical studies failed to find an 
association between HBD-1 level in diseased versus 
healthy subjects.14,45 The HBD-1 protein level was also 
higher in patients with periodontitis than in patients with 
gingivitis,11 as well as in healthy controls.46 By contrast, 
patients with mild chronic periodontitis exhibited a 
tendency toward higher expression of HBD-1 compared 
to the other groups.10 One possible explanation for these 
inconsistent findings is that HBD-1 contributes to the 
innate immune system. However, its involvement during 
the periodontal disease process remains unclear due to 
the strong induction of pro-inflammatory cytokines.14,47 
Nonetheless, polymorphism of the HBD-1 gene seems to 
be another reason. 
 
Gingival keratinocyte cells collected from patients 
with periodontitis and healthy subjects showed a 
significant upregulation of mRNA expression of HBD-1 
in healthy cells and downregulation in periodontitis cells 
in response to stimulation with TNFα (100, 150, and 200 
ng/ml).12 Wide variations in constitutive expression of 
HBD-1 have also been reported in response to different 
stimuli.48 One recent study clarified the mechanism by 
which a microbial metabolite, 10-Hydroxy-cis-12-
octadecenoic acid (HYA), reduced alveolar bone loss in a 
mouse model of periodontitis by finding that HYA 
induced a 1.4-fold increase in defensin (DEFB4A) 
expression and improved the epithelial barrier junction 
component in the epithelial cell, especially E-cadherin.49 
These findings might support the idea that HBD-1 
maintains homeostasis in both keratinocytes and 
epithelial cells.  
 
A critical issue that has attracted attention is the 
detection of HBD-1 mainly in the oral stratified 
epithelium and sulcular epithelium, but its absence in the 
junctional epithelium.6 This finding somehow opposes the 
proposed theory of a defense role for HBD-1, since the 
port of entry for pathogens is the junctional epithelium.47 
However, other studies have clarified that defensins 
derived from neutrophils might be directed to protect 
against periodontal disease since the neutrophil defensins 
are expressed in the junctional region.5 As shown in 
Figure 1, the colonization of bacteria and even the 
physiological response could promote the production of 
HBD-1. Although some periodontal pathogens, such as 
Aggregatibacter actinomycetemcomitans, Porphyro-
monas gingivalis, Treponema denticola, and Tannerella 
forsythia, can survive and invade gingival tissue,13 it is 
investigated that defensins are also able to deactivate the 
lipopolysaccharide activity of Gram-negative bacteria.2  
 
HBD-1 stimulates the production of chemo-attractant 
chemokines, including IL-8 and CCL2, in dendritic cells, 
thereby recruiting phagocytes and lymphocytes to the 
infection site.13 The epithelial cells and neutrophils in 
inflamed tissue also produce defensin in response to 
physiological and pathological conditions, thus HBD-1 
plays roles in both innate and adaptive immune system 
responses. It also triggers the attraction of monocytes, T-
lymphocytes, dendritic cells, and mast cells to the 
infection site,50 as summarized in Figure 2. 
 
The mechanism by which HBD-1 entrapped bacteria 
was also revealed by scanning electron microscopy 
images showing abundant HBD-1 within net-like 
structures surrounding the E. coli cells.8 Incubation of E. 
coli cells with HBD-1 resulted in the formation of these 
nets, supporting a previous hypothesis of an interaction 
between HBD-1 and the bacterial cell envelope.51,52 
Transmigration assays confirmed that      this entrapment 
system inhibited the translocation of Klebsiella 
pneumoniae from the upper to the lower compartment.8 
The net formation was also seen under physiological 
conditions in duodenal fluid, which contains high levels 
of proteases.8 Thioredoxin-modified HBD-1, also known 
as disulfide bond-modified HBD-1, showed an even more 
potent antimicrobial activity.37 These findings verified 
that net formation is an additional protective action of 
HBD-1. 
 
HBD-1 GENE POLYMORPHISM 
 
Polymorphism of HBD-1 has been proposed as the 
main reason for the conflicting genotype results seen in 
patients with periodontitis.10,11,15,46 Three poly-
morphisms in the DEFB1 5’ untranslated region (UTR), 
at     position   g.   -52G>A    (rs1799946),    g.    -44C>G 
(rs1800972),  and  g.  -20G>A  (rs11362),   appear  to  be  
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Figure 1. The distribution of human beta-defensin-1 
(HBD-1) in periodontal tissue. HBD-1 is found in the 
oral stratified epithelium and sulcular epithelium; while 
















Figure 2. Mechanism of HBD-1 suppression of 
periodontal disease. Epithelial cells and neutrophils 
produce defensin (HBD-1) in both physiological and 
pathological processes. In the pathological process, 
defensin will stimulate the recruitment of immature 
dendritic cells, create the antigen-defensin complex, form 
a net that entraps bacteria, and thereby modulate bacterial 
composition. Defensin also mediates the migration of T-
cells to the infected site.8,13 
 
involved in the secretion of HBD-1,52 as shown in Table 
1. These single nucleotide polymorphisms (SNPs) were 
significantly associated with the susceptibility of having 
periodontitis among Japanese18 and European 
patients,16,19,20 but not in Americans,17 suggesting ethnic 
differences. 
 
In brief, the association between DEFB1 g. -20G>A 
and periodontal conditions is inconsistent, with some 
studies claiming no association.16,17,53 By contrast,  the  g. 
-20G/G genotype was detected more frequently in 
periodontitis patients,20 and the g. -20A allele was 
confirmed to decrease DEFB1 gene expression.54,55 
Patients with diabetes mellitus (DM) also show genetic 
variations in the DEFB1 gene (SNP -20: G allele, GA, 
and GA genotypes) and the DEFB1 5’UTR haplotypes 
(GCG and ACG), which might be associated with the 
known susceptibility of patients with DM to 
periodontitis; patients with chronic periodontitis but 
without DM also show these variations.21 Therefore, the 
g. -20G polymorphism may be related to a greater 
production of HBD-1, which would lead to an immune 
system over-reaction and increase the risk of developing 
periodontitis.  
 
An association of the g. -44G/C DEFB1 SNP 
(rs1800972) with periodontitis susceptibility was also 
reported in Japanese patients with severe and moderate 
chronic periodontitis. The g. -44CC genotype was 
correlated with periodontitis (OD 2.510), severe chronic 
periodontitis (OR 4.154), and moderate-to-severe 
periodontitis (OR 4.038).18 Another study found no 
association of g. -44 C/G with early-onset periodontitis,56 
also known as juvenile or aggressive periodontitis. A 
further study demonstrated that the position -44 was 
influenced by the putative nuclear factor kappa beta 
(NFκB) binding site such that a change would alter the 
NFκB affinity and HBD-1 regulation at the transcription 
step.57  
 
The rare rs1800972 allele has been proposed to be a 
protective allele.58 By contrast, the rs1047031 variant 
alters the function of HBD-1 in the maintenance of the 
epithelial barrier.16 The rs1047031 SNP has five bp 
located inside the 3’ UTR and the sequence that includes 
the 5’ and 3’ UTRs shows no significant changes in the 
polymorphism.16 Therefore, SNP rs1047031 itself is 
assumed to increase the susceptibility to periodontal 
disease. 
 
POSSIBLE FURTHER STUDIES 
 
A recent classification of periodontal disease has been 
published, and both chronic and aggressive periodontitis 
are now combined into a single periodontitis group.59 For 
this reason, further clinical investigations of HBD-1 
expression or levels should be focused on the staging and 
grading of periodontitis rather than the concept of chronic 
or aggressive disease. HBD-1 is predominantly produced 
by epithelial cells that are distributed in the oral and 
sulcular epithelium; therefore, a mucosal swab is 
recommended to provide an epithelial sample of the 
marginal and sulcular gingiva. Further investigations on 
gene polymorphisms should also be conducted on larger 
numbers of racially matched subjects. Overall, the 
influence of the -52G>A (rs1799946), -44C>G 
(rs1800972), and -20G>A (rs11362) DEFB1 genes 
polymorphisms point to a clear pattern that is linked to 
the susceptibility to periodontitis.  
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In vitro and in vivo studies are still needed that focus 
on the antimicrobial effect of HBD-1 against periodontal 
bacteria, and many opportunities exist for exploration of 
the action of HBD-1 by selecting different study designs. 
The idea that HBD-1 acts as an immune-modulator is 
also promising because the current trends in periodontal 
therapy approaches are pointing toward host modulation 
therapy. Therefore, further investigations on the 
intracellular HBD-1 signaling pathways and HBD-1 





These investigations and studies show that the role of 
HBD-1 in maintaining homeostasis is undeniable, 
especially in periodontal tissue. The potential shown by 
HBD-1 against periodontal pathogens varies due to 
differences in the severity of the disease and in the 
patient’s genetic background, also known as 
polymorphism. Further investigations are needed to 
provide a better understanding of the involvement and 
















Total 3128 (German 
with CP (675), CP 
controls (262); German 
with AP (368), AP 
controls (1104); Dutch 
with CP (130), CP 
control (57); Dutch with 







The rs1800972 SNP was slightly associated in CP 
and AP groups. In details, it was driven by the low 
frequency of the rare G allele seen in AP, but not 
in CP 










No association between DEFB1 gene markers and 
periodontal disease was found 




Japan Total 105 (28 Severe 
CP, 13 Moderate-mild 







The DEFB1 -44C>G was associated with CP (OR 
2.51), particularly with severe CP (4.15) and with 
combined severe and moderate CP (4.04). -44 CC 
genotype may be associated with susceptibility to 









Association was found of URTD and P with the 
marker of DEFB1 -44C>G 
















DEFB1 -20G>A and -44C>G were found to be 
associated with CP 




Brazil Total 280 (116 







Association found for the DEFB1 -20G>A 
(rs11362); G allele, GA and GG genotypes were 
significantly more frequent in DM2+CP (59.5%, 
50% and 34%, respectively) and CP (61%, 44.2%, 
and 38.9%, respectively) than in healthy subject 
(26.8%, 36.2%, and 8.7%, respectively) 
Table 1.  Recent studies of HBD-1 gene polymorphism associated to periodontitis 
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